An oBservational retrospective Analysis of treatment patternS and Effectiveness of standard of CAre for Multiple Myeloma Patients Exposed to Lenalidomide and a Proteasome Inhibitor: BasecaMMp Study
Clinical Lymphoma Myeloma and Leukemia · 2026
DOI: 10.1016/j.clml.2026.01.013 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2026. Verfasst von Klaus Martin Kortüm und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine II, Würzburg University Hospital, Würzburg, Germany. Hauptthemen laut MEDLINE: Multiple Myeloma, Lenalidomide, Proteasome Inhibitors, Standard of Care. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer.
Abstract (Originalsprache)
INTRODUCTION: Most patients with relapsed or refractory multiple myeloma (RRMM) have previously received lenalidomide (LEN) and proteasome inhibitors (PIs). This real-world study describes treatment patterns and clinical outcomes for RRMM patients post-LEN and PI in Germany. METHODS: The BasecaMMp cohort included patients with prior LEN and PI therapy within the first to third line of treatment (LOT) between May 2016 and December 2023. Patient characteristics, treatment regimens and progression-free survival (PFS), overall survival (OS) and time to next treatment (TTNT) were analyzed. RESULTS: Of 1834 patients included (median age: 72.5 years; 59.5% male; median of 2 prior LOTs), around 30.4% were double-refractory, and 47.7% were LEN-refractory. Index therapies (first therapies received after exposure to LEN and a PI in the first to third lines) were highly heterogeneous. Median PFS was 12.7 (95% confidence interval [CI], 12.2-13.14) months overall and 11.3 (95% CI, 10.3-12.1) months in LEN-refractory patients, while median OS was 37.1 (95% CI, 34.2-40.7) months overall and 34.3 (95% CI, 31.1-41.0) months in LEN-refractory patients. CONCLUSION: These findings highlight the lack of a clear standard of care, poor clinical outcomes, and the need for more effective therapies and treatment strategies for this population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine II, Würzburg University Hospital, Würzburg, Germany.
- HTA, Value and Evidence, Hematology, Pfizer Ltd., Dublin, Ireland. Electronic address: James.Lawless-Farrell@pfizer.com.
- Oncology Medical - Global Hematology, Pfizer Ltd., London, United Kingdom.
- Statistics, Pfizer Ltd., New York City, NY.
- EVA, Cytel Incl., Berlin, Germany.
- EVA, Cytel Inc., London, United Kingdom.
Förderung
- Pfizer
Zitieren
APA
Kortüm, K. M., Farrell, J., Ashman, O., Nador, G., Cislo, P., Luna, J., Lehne, M., O'Neill, K., Rückert, M., Strobel, K., & Theurich, S. (2026). An oBservational retrospective Analysis of treatment patternS and Effectiveness of standard of CAre for Multiple Myeloma Patients Exposed to Lenalidomide and a Proteasome Inhibitor: BasecaMMp Study. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2026.01.013
Vancouver
Kortüm KM, Farrell J, Ashman O, Nador G, Cislo P, Luna J, et al. An oBservational retrospective Analysis of treatment patternS and Effectiveness of standard of CAre for Multiple Myeloma Patients Exposed to Lenalidomide and a Proteasome Inhibitor: BasecaMMp Study. Clinical Lymphoma Myeloma and Leukemia. 2026. doi:10.1016/j.clml.2026.01.013
BibTeX
@article{Kortm2026,
author = {Kortüm, Klaus Martin and Farrell, James and Ashman, Olivia and Nador, Guido and Cislo, Paul and Luna, Jaime and Lehne, Moritz and O'Neill, Keltie and Rückert, Markus and Strobel, Kai and Theurich, Sebastian},
title = {An oBservational retrospective Analysis of treatment patternS and Effectiveness of standard of CAre for Multiple Myeloma Patients Exposed to Lenalidomide and a Proteasome Inhibitor: BasecaMMp Study},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2026},
doi = {10.1016/j.clml.2026.01.013}
}
EUVIMED